An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX005425 Tablets in Subjects With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors
Latest Information Update: 14 Oct 2025
At a glance
- Drugs JMKX 005425 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jemincare
Most Recent Events
- 14 Oct 2025 New trial record